U.S. researchers have uncovered new information about how metastatic prostate cancer becomes resistant to androgen-deprivation therapy, which suppresses circulating testosterone, the hormone that promotes prostate cancer growth. Androgen therapy, which involves the use of surgical castration or medical castration with testosterone-blocking drugs, does extend survival time for patients, but it isn't a cure. Eventually, the cancer becomes resistant to androgen deprivation and continues to grow.

Full story: medicinenet.com